Dendritic cells (DCs) comprise two functionally distinct subsets: plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDCs are specialized in rapid and massive secretion of type I interferon (IFN-I) in response to nucleic acids through Toll like receptor (TLR)-7 or TLR-9. In this report, we characterized a CD56+DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. In addition, CD56+DCs cluster together with mDCs but not pDCs by genome-wide transcriptional profiling. Accordingly, CD56+DCs functionally resemble mDCs by producing IL-12 upon TLR4 stimulation and priming naïve T cells without prior activation. These data suggest that the CD56+DCs represent a novel mDC subset mixed with some pDC features. A CD4+CD56+hematological malignancy was classified as blastic plasmacytoid dendritic cell neoplasm (BPDCN) due to its expression of characteristic molecules of pDCs. However, we demonstrated that BPDCN is closer to CD56+DCs than pDCs by global gene-expression profiling. Thus, we propose that the CD4+CD56+neoplasm may be a tumor counterpart of CD56+mDCs but not pDCs.
Yu, H., Zhang, P., Yin, X., Yin, Z., Shi, Q., Cui, Y.a., et al. (2015). Human BDCA2+CD123+CD56+dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. PROTEIN & CELL, 6(4), 297-306 [10.1007/s13238-015-0140-x].
Human BDCA2+CD123+CD56+dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset
Piccaluga, Pier Paolo;
2015
Abstract
Dendritic cells (DCs) comprise two functionally distinct subsets: plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDCs are specialized in rapid and massive secretion of type I interferon (IFN-I) in response to nucleic acids through Toll like receptor (TLR)-7 or TLR-9. In this report, we characterized a CD56+DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. In addition, CD56+DCs cluster together with mDCs but not pDCs by genome-wide transcriptional profiling. Accordingly, CD56+DCs functionally resemble mDCs by producing IL-12 upon TLR4 stimulation and priming naïve T cells without prior activation. These data suggest that the CD56+DCs represent a novel mDC subset mixed with some pDC features. A CD4+CD56+hematological malignancy was classified as blastic plasmacytoid dendritic cell neoplasm (BPDCN) due to its expression of characteristic molecules of pDCs. However, we demonstrated that BPDCN is closer to CD56+DCs than pDCs by global gene-expression profiling. Thus, we propose that the CD4+CD56+neoplasm may be a tumor counterpart of CD56+mDCs but not pDCs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
